- Pegylovaný interferon beta-1a v klinické praxi2018 | Second Faculty of Medicine
- Coping with flu-like symptoms and injection site reactions in the treatment subcutaneous interferon beta-1a od multiple sclerosis2014 | Faculty of Medicine in Pilsen
- Report of University Hospital Hradec Králové to the clinical trial protocol No: WA21092Publication without faculty affiliation
- A comparison of efficacy of subcutaneous interferon beta-1a 44 mu g, dimethyl fumarate and fingolimod in the real-life clinical practise - a multicenter observational study2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- AMETYST - results of an observational phase IV clinical study evaluating the effect of intramuscular interferon beta-1a therapy in patients with clinically isolated syndrome or clinically definite multiple sclerosis2017 | First Faculty of Medicine
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis2015 | First Faculty of Medicine
- AMETYST - Observational Phase IV Study Following the Influence of Intramuscularly Administered Interferon Beta-1a in Patients with Clinically Isolated Syndrome/Clinically Definite Multiple Sclerosis2014 | First Faculty of Medicine
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | First Faculty of Medicine
- Erratum - Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Im-munity in a Group of Women with Multiple Sclerosis (vol 86, pg 334, 2023)2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE2018 | First Faculty of Medicine
- Treatment intramuscular interferon beta-1a2013 | First Faculty of Medicine
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a2021 | First Faculty of Medicine
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | First Faculty of Medicine
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?2017 | First Faculty of Medicine
- A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis2005 | First Faculty of Medicine
- A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis2005 | Faculty of Physical Education and Sport
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine
- Indicators of clinical activity in multiple sclerosis and their influence treatment2014 | Faculty of Medicine in Hradec Králové
- Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study2017 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | First Faculty of Medicine
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a2018 | First Faculty of Medicine
- Interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: preliminary clinical and MRI data from a two-year, double-blind, randomized, placebo-controlled studyPublication without faculty affiliation
- Interferon beta-1a combination with azathioprine and low-dose steroids (ASA study) for relapsing-remitting multiple sclerosis clinical and MRIdata from 2-years double blind, randomised, placebo controled studyPublication without faculty affiliation
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | Publication without faculty affiliation
- Intramuscular Interferon beta-1a, Azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy resultsPublication without faculty affiliation
- Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Early magnetic resonance imaging predictors of clinical progression after 48months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a2015 | First Faculty of Medicine